| Published Version Download ( PDF | 1MB) | License: Creative Commons Attribution 4.0 |
SARS-CoV-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19
Article
Glück, Vivian, Grobecker, Sonja, Tydykov, Leonid, Salzberger, Bernd
, Glück, Thomas, Weidlich, Tanja, Bertok, Manuela, Gottwald, Christine, Wenzel, Jürgen J.
, Gessner, André
, Schmidt, Barbara
and Peterhoff, David
(2021)
SARS-CoV-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19.
Infection 49 (4), pp. 739-746.
DOI to cite this document: 10.5283/epub.52693
Abstract
Objective To follow serological immune responses of front-line healthcare workers after PCR-confirmed COVID-19 for a mean of 30 weeks, describe the time-course of SARS-CoV-2 spike protein-specific IgG, IgA and IgM levels and to identify associations of the immune response with symptoms, demographic parameters and severity of disease. Methods Anti-SARS-CoV-2 S protein-specific IgG, IgA and IgM ...
Objective To follow serological immune responses of front-line healthcare workers after PCR-confirmed COVID-19 for a mean of 30 weeks, describe the time-course of SARS-CoV-2 spike protein-specific IgG, IgA and IgM levels and to identify associations of the immune response with symptoms, demographic parameters and severity of disease. Methods Anti-SARS-CoV-2 S protein-specific IgG, IgA and IgM antibodies were measured at three time points during the 30-week follow-up. COVID-19-specific symptoms were assessed with standardized questionnaires. Results 95% of the participants mounted an IgG response with only modest decline after week 12. IgG-type antibodies were still detectable in almost 90% of the subjects at 30 weeks. IgA and IgM responses were less robust and antibody titers decreased more rapidly. At 30 weeks, only 25% still had detectable IgA-type and none had IgM-type antibodies. Higher age and higher disease severity were independently associated with higher IgG antibody levels, albeit with wide variations. Conclusion Serological immune responses after COVID-19 show considerable inter-individual variability, but show an association with increasing age and higher severity of disease. IgG-type anti-SARS-CoV-2 antibodies remain positive in 90% of the individuals 30 weeks after onset of symptoms.
Alternative links to fulltext
Involved Institutions
Details
| Item type | Article | ||||
| Journal or Publication Title | Infection | ||||
| Publisher | SPRINGER HEIDELBERG | ||||
| Open Access Type | DEAL (Springer) | ||||
| Place of Publication | HEIDELBERG | ||||
| Volume | 49 | ||||
| Number of Issue or Book Chapter | 4 | ||||
| Page Range | pp. 739-746 | ||||
| Date | 10 March 2021 | ||||
| Date of publication | 01 Aug 2022 08:25 | ||||
| Institutions | Medicine > Lehrstuhl für Innere Medizin I Medicine > Lehrstuhl für Medizinische Mikrobiologie und Hygiene | ||||
| Identification Number |
| ||||
| Keywords | INFECTION; SARS-CoV-2; COVID-19; Serological immune response; Antibody titer; ELISA; Severity of disease | ||||
| Dewey Decimal Classification | 600 Technology > 610 Medical sciences Medicine | ||||
| Status | Published | ||||
| Refereed | Yes, this version has been refereed | ||||
| Created at the University of Regensburg | Yes | ||||
| URN of the UB Regensburg | urn:nbn:de:bvb:355-epub-526932 | ||||
| Item ID | 52693 |
Download Statistics
Download Statistics